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IRRADIATION OF CELLULAR BLOOD COMPONENTS WITH COBALT 60
IS VERY EFFICIENT AND SAFE IN THE PREVENTION OF TRANSFUSION
ASSOCIATED GRAFT VERSUS HOST DISEASE (TA-GVHD) IN THE ALLO-
GENEIC TRANSPLANT SETTING
Karduss, A.1, Leon, E.2, Buitrago, L.3, Gomez, L.P.1, Jimenez, J.A.1,
Reyes, P.1, Coll, Y.1 1Marrow Transplant Program - Instituto de Can-
cerologia - Clinica las Americas, Medellin, Colombia; 2Radiotherapy
Department - Instituto de Cancerologia - Clinica las Americas, Medellin,
Colombia; 3Blood Bank - Clinica las Americas, Medellin, Colombia.
For the prevention of TA-GHVH in patients who received a
allogeneic stem cell transplant is mandatory the gamma irradiation
of the all cellular blood components. This irradiation is usually
done with Cesium 137 and with a special blood bank irradiators.
However these devices are expensive; because that, in developing
countries, is frequent the utilization of Cobalt 60 and the same
device that is used in the radiotherapy department, instead of blood
bank irradiators. However the information about the efﬁciency and
safety of this procedure is scarce. We present our experience with
this technique.
From Dec 2002 to Dec 2005 thirty patients received a allogeneic
stem cell transplant and 28 were analysed . The stem cells source
was: peripheral blood 25, unrelated cord blood 2, bone marrow 1.
The irradiation of the blood components was performed with
Cobalt 60 1.24 Mev- (theratron 780 C); the irradiation ﬁeld was
calculated for covering all of the bag surface and a dose of 3.5 Gy
was administered to the mild plane of the bag.
158 blood concentrates were transfused, 68 red cell (X:2.5 per
patient), and 90 platelets (3.2 per patient). The pre transfusion
median hemoglobin and platelet levels were 7.63 g/dl and 12.000/
ul; after transfusion was a median increase of 2.3 gm/dl (0.6-4.7) in
hemoglobin and 18.000/ul (0-140.000) in platelets.
There was no any case of TA-GVHD. Four patients developed
pos transplant aGVHD, in all of the cases the disease began 50 days
or more after the last transfusion , there were no pancytopenia and
the aGVHD was resolved completely with the treatment.
Conclusion:
In receptors of allogeneic stem cell transplant the gamma irradi-
ation of blood components with Cobalt 60 and the same device
wich is used for patients radiotherapy is 100% effective and safe in
the prevention of TA-GVHD. This is a very good alternative in
centers without a blood bank irradiator.
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SUCCESSFUL PHASE II TRIAL USING MESENCHYMAL STEM CELLS
(MSC) IN COMBINATION WITH STEROID THERAPY FOR THE PRIMARY
TREATMENT OF ACUTE GRAFT-VS-HOST DISEASE (AGVHD)
Kebriaei, P.1, Isola, L.2, Bahceci, E.3, Holland, H.K.4, Rowley, S.5,
McGuirk, J.6, Devetten, M.7, Jansen, J.8, Herzig, R.9, Schuster, M.10,
Uberti, J.11 1MD Anderson Cancer Center, Houston, TX; 2Mount Sinai
Hospital, NY, NY; 3Yale University, New Haven, CT; 4Northside
Hospital, Atlanta, GA; 5Hackensack University, Hackensack, NJ; 6Kan-
sas City Cancer Center, Kansas City, MO; 7Univ of Nebraska Medical
Center, Omaha, NE; 8St Fancis Hospital, Beech Grove, IN; 9University
of Louisville Hospital, Louisville, KY; 10NY Presbyterian Hospital, NY,
NY; 11Karmanos Cancer Institute, Detroit, MI.
AGVHD is a major cause of morbidity and mortality after
allogeneic stem cell transplantation (SCT). Primary treatment
of aGVHD with steroids achieves complete response (CR) rates
of only 20-40%. MSC may provide effective GVHD therapy. In
this study, Prochymal, an ex-vivo cultured MSC derived from
unrelated donors, was used in combination with conventional
steroid therapy for primary treatment of aGVHD. Pts were
eligible if they had newly diagnosed aGVHD, grades II-IV, after
undergoing related or unrelated SCT, or donor lymphocyte
infusion (DLI). Study endpoints were drug safety and aGVHD
response rates by day 28 after infusion. Pts were randomized to
2 doses of Prochymal: 2 (low) or 8 million (high) cells/kg.
Prochymal was initiated along with steroid therapy at time of
aGVHD diagnosis. 2 Prochymal infusions were administered
3-5 days apart within 72 hrs of steroid initiation. Tacrolimus,
cyclosporine, or MMF were maintained for GVHD prophylaxis
. Pts were maintained on steroids (2 mg/kg/d) for at least 1 week
with objective of subsequently tapering off steroids. 32 pts (23
males, 9 females) were enrolled, and 31 were evaluable with
median age 52 yrs (range 34-67). AGVHD developed following
matched sibling (n15) or matched unrelated SCT (n13), or
DLI (n4). Distribution of aGVHD is described in table below.
Pts were randomized to low (n17) or high (n15) Prochymal
dose. 90% of pts (n28) initially responded to aGVHD treat-
ment: 21 achieved CR with no evidence of GVHD, and 7
achieved PR with a reduction in 1 organ stage. 100% of pts
initially diagnosed with skin GVHD had a response to treat-
ment, and 83% of pts with GVHD involving GI alone or with
other organs had a response. 9 pts (31%) eventually required a
second line agent to control aGVHD. Non-relapse survival at
day 100 was 79.3% with 8 pts dying at a median of 48 days
(range 13-58): aGVHD (n2), intracranial bleed (n1), relapse
(n1), infection (n4). No infusional toxicities or discontinu-
ation of treatment was observed. 1 pt developed atrial ﬁbrilla-
tion 24 hrs following the second Prochymal infusion. No ec-
topic tissue formation was noted by CT scans at day 28.
Addition of Prochymal to standard steroid therapy for the pri-
mary treatment of aGVHD resulted in a high response rate with
minimal added toxicity. This trial demonstrates the potential of
using a universal, cellular product for the treatment of aGVHD.
A phase III clinical trial has been initiated to conﬁrm these
promising results.
Grade and Distribution of GVHD
Grade (no. pts) II(21) III (8) IV(3)
Organ (no. pts) GI(12) Skin(13) GI/Skin(5) GI/Liver(2)
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INITIAL SELECTION OF HIGH AFFINITY CD25 CELLS INCREASES THE
PURITY OF CD4CD25FOXP3 T REGULATORY CELLS EXPANDED
IN MEDIUM CONTAINING RAPAMYCIN
Keever-Taylor, C.A.1, Tsao, A.1, Davies, B.1 1Medical College of Wis-
consin, Milwaukee, WI.
CD4 T regulatory cells (Tregs) with potent suppressor ac-
tivity are marked by high levels of CD25 and expression of the
transcription factor, Foxp3. We described an approach to isolate
and expand Tregs using a single CD25-enrichment on a MACS
column, activation by CD3/CD28-coated beads, and culture in
medium containing rapamycin (Keever-Taylor et al, submitted).
We achieved 10-fold expansion at day 10 of cells with potent
suppressor activity that were enriched for
CD4Foxp3CD27 cells using 1-10 ng/mL rapamycin. After
21 days the cells expanded 200-fold but although still enriched
for CD4Foxp3CD27 cells compared cultures grown with-
out rapamycin, the suppressor activity and Foxp3 content had
greatly declined. We have further optimized conditions by ex-
ploring two approaches: 1) increase the starting purity of
CD4Foxp3 cells, and 2) increase the dose of rapamycin to
further inhibit the expansion of activated T cells. We compared
the purity of Tregs when 1, 2, or the previously used 4 	L of
CD25-coated beads/107 starting cells were used to bind the
CD25 cells and 1 versus 2 selection columns. Data showed
that after passage through one column the % of CD4 cells
expressing Foxp3 was 27.3%, 54.3% and 31.7% with 1, 2, or 4
	L beads, respectively. The %CD4Foxp3 cells further in-
creased to 51.9%, 64.1% and 60%, respectively after a passage
through a second column. Therefore, subsequent experiments
used 2 	L beads and sequential passage through two columns.
Doses of rapamycin from 50-200 ng/mL were increasing toxic,
with few cells recovered from the expansion cultures. However,
at the previously used doses of 5-10 ng/mL the
%CD4Foxp3 cells after 22-24 days averaged 37.37.1%,
similar to the 4220% seen at day 10 in our previous experi-
ments and signiﬁcantly higher than the 232% previously seen
at day 21 when suppressor activity had declined. In contrast only
4.70.4% of the recovered CD4 cells expressed Foxp3 in the
absence of rapamycin, similar to the 53% shown for single
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column-passed fractions at day 21. In summary our data show
that by increasing the starting purity of CD4Foxp3CD27
cells a greater expansion of the Treg population can be
achieved, making it more feasible to obtain clinically useful
doses of Treg for immunotherapy protocols to prevent or treat
GVHD. Rapamycin at doses of 5-10 ng/mL inhibits the expan-
sion of cells without the phenotype and function of Tregs, but
higher doses (50-200 ng/mL) are toxic to Tregs.
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TREATMENT OF STEROID REFRACTORY, SEVERE ACUTE GRAFT VERSUS
HOST DISEASE WITH EXPANDED MESENCHYMAL STEM CELLS IN CHIL-
DREN HAVING UNDERGONE ALLOGENEIC STEM CELL TRANSPLANTA-
TION: A SINGLE CENTER EXPERIENCE
Ball, L.M.1, Kollen, W.J.W.1, Lankester, A.1, Roleofs, H.2,
Fibbe, W.E.2, Egeler, R.M.1 1Dept. Pediatrics, Leiden University Med-
ical Center, Leiden, RC, Netherlands; 2Immunohematology and Stem
Cell Research, Leiden University Medical Center, Leiden, RC, Nether-
lands.
Despite advances in pre-transplant immune suppression and do-
nor HLA typing methods acute graft versus host disease (aGvHD)
remains a signiﬁcant problem following allogeneic HSCT. Steroid
therapy is the treatment of choice in severe aGvHD. Steroid
non-responsive aGvHD is associated with increased morbidity and
more importantly death due to organ damage and/or infection
related to the use of continuing immune suppression. Second line
treatments continue to be evaluated. Whatever their initial effects,
presently they have had little impact on overall survival.
Mesenchymal stem cells (MSCs) are poor antigen presenting
cells, not expressing MHC class II or co-stimulatory molecules.
They down regulate allo-reactive T cell responses when added to
mixed lymphocyte cultures. MSCs alter cytokine excretion proﬁles
of dendritic cells, naı¨ve and effector T cells, and NK cells inducing
a more tolerant phenotype.
MSCs have been used successfully in a child with resistant
aGvHD (le Blanc. Lancet 2004).
We conducted an ethically committee approved prospective
phase I/II study of co-infusion of expanded MSCs for treatment of
children with steroid refractory, grade II-IV aGVHD.
MSCs, isolated from parental donor marrow were expanded
under GMP conditions. MSCs either as haploidentical or 3rd party.
Patient characteristics receiving MSCs for steroid refractory GvHD.
LUMC 2005-2006
UPN 1 UPN 2 UPN 3 UPN 4
Male Male Male Female
MDS RC Omens Fanconi
anemia
JMML
12y, 3mo 1 yr, 4mo 6yr, 10mo 1yr, 7mo
Sibling ID ORD ID x 2 Matched UD
BMT
Matched Cord
Blood
GvHD 4
(Skin/GI/
Liver)
4 GI
acute/chronic
plus
CMV/graft
failure
4 (skin/GI/
Liver)
4 GI plus AdV
Steroid/CSA/
Tacrolimus/
MMF
Steroid/
Tacrolimus/
MMF
Steroid/CSA/
Anti TNF	/
anti CD25
Steroid/
Tacrolimus/
MMF
MSC1 3rd
party
MSC2 haplo MSC1 3rd
party
MSC2 3rd party
1.1  106/kg 1.8  106/kg 2.3  106/kg 1.76  106/kg
Male 33 years Female 25 years Male 33 years Female 25 years
2 infusions 2 infusions 2 infusions 2 infusions
430 CR No response 430 CR 430 CR
Died
Klebsilella
sepsis
Died
CMV/GvHD
Alive Limited
cGvHD
skin
Alive small
bowel fibrosis
UPN 5 UPN 6 UPN 7 UPN 8
Male Female Male Female
Kostmaan
syndrome
EBV induced
HLH
MDS RC MDS RC
monosomy 7
3yr, 10mo 6yr, 4mo 13yr, 2 mo 4yr, 2mo
Matched UD
BMT
Cord Plus Haplo
and MM UD
BMT
MUD x 3,
DLI’s
MM Cord blood
4GI acute/
chronic
4 Liver 4 (Skin/GI/
Liver)
4 (Skin/GI/Liver)
AdV
Steroid/CSA/
Anti TNF	/
anti CD25
Steroid/CSA/
Tacrolimus
Steroid/MMF Steroid/CSA/
Tacrolimus
MSC3 3rd
party
MSC2 3rd party MSC1 3rd
party
MSC4 3rd party
1.7 106/kg 2.0 106/kg 1.2  106/kg 2.2  106/kg
Female 35
years
Female 25 years Male 33 years Male 36 years
2 infusions 1 infusion 2 infusions 2 infusions
PR; relapsed
GvHD
Not evaluated 430 CR 430 CR
Died
infection/
GvHD
Died EBV
reactivation
Alive liver
dysfunction
Alive
UPN - Unique patient number; CR - complete response: PR -
partial response; AdV - adenovirus; CMV - cytomegalovirus;
EBV - Epstein Barr virus; HLH - hemaphagocytic lymphohis-
tiocytosis; MDS RC - myelodysplastic syndrome and refractory
cytopenia; JMML - Juvenile myelomonocytic leukemia; CSA -
cyclosporine
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BLOCKING LFA-1 ACTIVATION WITH LOVASTATIN PREVENTS GRAFT-
VERSUS-HOST DISEASE IN MOUSE BONE MARROW TRANSPLANTATION
Wang, Y.1, Li, D.1, Jones, D.1, Bassett, R.1, Sale, G.E.2, Khalili, J.1,
Komanduri, K.V.1, Couriel, D.P.1, Champlin, R.E.1, Molldrem, J.J.1,
Ma, Q.1 1University of Texas M.D. Anderson Cancer Center, Houston,
TX; 2Fred Hutchinson Cancer Research Center, Seattle, WA.
Leukocyte function associated antigen-1 (LFA-1) regulates T cell
adhesion and activation. LFA-1 is constitutively expressed on cell
surface in an inactive state. The control of LFA-1 activation is
critical in inﬂammatory and immune responses. We demonstrated
previously that the I-domain, the ligand binding site of LFA-1,
changes from the low-afﬁnity state to high-afﬁnity state upon
activation. Therapeutic antagonist, such as lovastatin, stabilizes the
I-domain in the low-afﬁnity state and inhibits the LFA-1 activa-
tion. Here, we report that lovastatin can block mouse T cell
adhesion and proliferation in vitro. First, we demonstrated that
lovastatin treatment reduced the mortality and morbidity in the
mouse GVHD model. Lovastatin treatment signiﬁcantly decreased
GVHD mortality with 80% mice survived over 28 days, whereas
more than 70% of the control mice died within the ﬁrst 10 days,
and the p values was 0.045. There were signiﬁcantly reduced tissue
damages in the skin, intestine and liver of lovastatin-treated mice.
Second, we found lovastatin treatment reduced donor T cell hom-
ing to lymph nodes. There was a 65% reduction of CD4 T cells
homing to lymph nodes in lovastatin treatment group compared to
control. The reduction of CD8 T cells was greater with about
76% less cells homing to lymph nodes in the lovastatin treatment
group. Third, we found lovastatin treatment reduced donor-de-
rived T cell proliferation in vivo. There were 37% CD4 and 31%
CD8 T cells remained undivided in the lymph nodes of the
control mice at day 4 post-transplant. The lovastatin-treated mice
had reduced proliferation kinetics of both CD4 and CD8 T
cells with about 55% and 42% remained undivided. In the control
lymph nodes, there were 42% CD4 and 59% CD8 T cells
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